Analyst Caitlin Cronin of Canaccord Genuity maintained a Buy rating on REPRO-MED Systems (KRMD – Research Report), retaining the price target of $5.00.
Caitlin Cronin’s rating is based on REPRO-MED Systems’ strong financial performance and strategic growth plans. The company exceeded revenue and margin expectations, ending the year with a solid cash position and demonstrating positive cash flow. This financial strength is complemented by a roadmap for 2025 that includes significant revenue growth driven by the SCIg market, new collaborations, and expansion into the Japanese market.
Furthermore, the company is actively pursuing innovation with multiple 510(K) submissions planned for 2025 and 2026, which are expected to enhance its core platform and Novel Therapies. The renaming of its Novel Therapies segment to Pharma Services and Clinical Trials reflects a strategic focus on pre-commercial pharma collaborations. Despite potential competitive pressures, the company’s operational cash flow expectations and international expansion plans provide a solid foundation for achieving its near and long-term objectives, justifying the Buy rating.